OPKO Licensee TESARO Announces Successful Achievement of Primary and All Secondary Endpoints in Third and Final Phase 3 Trial of Rolapitant

[Business Wire] – OPKO Health, Inc. , reported that its licensee, TESARO, Inc. , announced positive top-line results from the third and final Phase 3 trial of rolapitant, an investigational neurokinin-1 receptor antagonist in development for the preventi more

View todays social media effects on OPK

View the latest stocks trending across Twitter. Click to view dashboard

See who OPKO is hiring next, click here to view